XCancer

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Description:

Patients will be treated with GD2-SADA and 177Lu-DOTA to study the safety and how well participants tolerate the treatment.

Sponsor:

Y-mAbs Therapeutics, Inc.

Government Study Link:

NCT05130255 - Click here to see study on

ClinicalTrials.gov